These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21348515)

  • 1. Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands.
    Tu Z; Li S; Cui J; Xu J; Taylor M; Ho D; Luedtke RR; Mach RH
    J Med Chem; 2011 Mar; 54(6):1555-64. PubMed ID: 21348515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands.
    Li A; Mishra Y; Malik M; Wang Q; Li S; Taylor M; Reichert DE; Luedtke RR; Mach RH
    Bioorg Med Chem; 2013 Jun; 21(11):2988-98. PubMed ID: 23618707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent molecular probes for dopamine D2-like receptors.
    Huber D; Löber S; Hübner H; Gmeiner P
    Bioorg Med Chem; 2012 Jan; 20(1):455-66. PubMed ID: 22100258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analogues of Arylamide Phenylpiperazine Ligands To Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity.
    Hayatshahi HS; Xu K; Griffin SA; Taylor M; Mach RH; Liu J; Luedtke RR
    ACS Chem Neurosci; 2018 Dec; 9(12):2972-2983. PubMed ID: 30010318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
    Salama I; Hocke C; Utz W; Prante O; Boeckler F; Hübner H; Kuwert T; Gmeiner P
    J Med Chem; 2007 Feb; 50(3):489-500. PubMed ID: 17266201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands.
    Peng X; Wang Q; Mishra Y; Xu J; Reichert DE; Malik M; Taylor M; Luedtke RR; Mach RH
    Bioorg Med Chem Lett; 2015 Feb; 25(3):519-23. PubMed ID: 25556097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands.
    Mach RH; Huang Y; Freeman RA; Wu L; Vangveravong S; Luedtke RR
    Bioorg Med Chem Lett; 2004 Jan; 14(1):195-202. PubMed ID: 14684327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands.
    Leopoldo M; Berardi F; Colabufo NA; De Giorgio P; Lacivita E; Perrone R; Tortorella V
    J Med Chem; 2002 Dec; 45(26):5727-35. PubMed ID: 12477356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.
    Rangel-Barajas C; Malik M; Taylor M; Neve KA; Mach RH; Luedtke RR
    J Neurochem; 2014 Nov; 131(4):418-31. PubMed ID: 25041389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
    Vangveravong S; Zhang Z; Taylor M; Bearden M; Xu J; Cui J; Wang W; Luedtke RR; Mach RH
    Bioorg Med Chem; 2011 Jun; 19(11):3502-11. PubMed ID: 21536445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands.
    Chu W; Tu Z; McElveen E; Xu J; Taylor M; Luedtke RR; Mach RH
    Bioorg Med Chem; 2005 Jan; 13(1):77-87. PubMed ID: 15582454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
    J Med Chem; 1998 Nov; 41(24):4903-9. PubMed ID: 9822559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D(4) receptors.
    Lacivita E; De Giorgio P; Lee IT; Rodeheaver SI; Weiss BA; Fracasso C; Caccia S; Berardi F; Perrone R; Zhang MR; Maeda J; Higuchi M; Suhara T; Schetz JA; Leopoldo M
    J Med Chem; 2010 Oct; 53(20):7344-55. PubMed ID: 20873719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.
    Hackling A; Ghosh R; Perachon S; Mann A; Höltje HD; Wermuth CG; Schwartz JC; Sippl W; Sokoloff P; Stark H
    J Med Chem; 2003 Aug; 46(18):3883-99. PubMed ID: 12930150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, in silico, and in vitro studies of novel dopamine D
    Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
    Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
    J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenylpiperazinylmethylheterocycle derivatives: synthesis and dopamine receptor binding profiles.
    Abadi AH
    Arch Pharm (Weinheim); 2004 Jul; 337(7):383-90. PubMed ID: 15237388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.
    Newman AH; Grundt P; Cyriac G; Deschamps JR; Taylor M; Kumar R; Ho D; Luedtke RR
    J Med Chem; 2009 Apr; 52(8):2559-70. PubMed ID: 19331412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a bivalent dopamine D₂ receptor agonist.
    Kühhorn J; Götz A; Hübner H; Thompson D; Whistler J; Gmeiner P
    J Med Chem; 2011 Nov; 54(22):7911-9. PubMed ID: 21999579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.